Released Nov 9, 2022, before the open
10-Q filed Nov 9, 2022, 40 days after period end · 0001171843-22-007269
Q3 2022 · 10-Q
Revenue—
Net Income-$11.98M-$11.98M N/M vs Q3 2021N/M vs Q2 2022
EPS, diluted—
Operating Income-$12,598,000N/M
Operating Cash Flowderived-$10,942,000N/M
Free Cash Flowderived-$10,969,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | -$11.98M | -$5.98M | -$9.15M | -$8.55M |
| EPS Diluted | — | -$0.10 | -$0.18 | -$1.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR